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1  | INTRODUC TION
Renal	 transplantation	 (RT)	 is	 the	 treatment	 of	 choice	 for	 eligible	
patients	with	end-	stage	 renal	disease	 (ESRD).	Whereas	 short-	and	
intermediate-	term	outcomes	of	renal	allografts	have	been	improved	
due	 to	 fewer	 early	 rejections	 and	 eventually	 through	better	 stan-
dardized immunosuppressive treatment strategies, evidence that 
these	effects	have	significantly	enhanced	long-	term	transplant	kid-
ney survival is still missing.1,2 Therefore, the induction of tolerance 
is considered as the ultimate goal in the field of transplantation. 
Currently,	the	only	clinically	successful	way	to	induce	donor-	specific	
tolerance	is	to	establish	full	or	mixed	chimerism	through	hematopoi-
etic stem cell transplantation (HSCT).3
Since	the	concept	of	chimerism	leading	to	selective	donor-	specific	
tolerance	 has	 been	 developed	 in	 the	 past	 century	 by	 Billingham,	
Medawar, and colleagues,4	 substantial	 progress	 has	 been	made	 in	
terms of preconditioning and the understanding of relevant path-
ways involved herein.3 However, despite promising results in murine 
studies,	its	widespread	use	has	been	hampered	by	the	cytotoxic	pre-
conditioning,	which	is	currently	required	for	bone	marrow	transplan-
tation. Clinically, the first evidence of tolerance through HSCT was 
delivered	by	Sayegh	et	al	in	1991,	who	described	a	30-	year-	old	man,	
diagnosed	with	acute	myelomonocytic	 leukemia	and	a	14-	year-	old	
girl	with	acute	nonlymphocytic	leukemia.	Both	received	HSCTs	from	
their	HLA-	identical	brothers.	After	a	few	years	and	gradual	deterio-
ration of their renal function, the original stem cell donors agreed to 
also	donate	a	kidney.	Except	for	small	maintenance	doses	of	steroids,	
no immunosuppression was given in the further course and trans-
plant	kidney	function	remained	stable.5	Based	on	this	success	more	
case	reports	followed,	including	HLA-	mismatched	donors,	who	suc-
cessfully donated renal transplants after HSCT.6–21
Due	to	a	full	donor	chimerism	in	these	patients,	a	robust	state	of	
tolerance	for	the	donated	organ	is	expected.	Nevertheless,	most	of	
these	patients	received	at	least	short-	term	immunosuppression	after	
transplantation. This was done not only to prevent renal allograft 
rejection	 but	 also	 to	 prevent	 graft-	versus-	host	 disease	 (GVHD),	
which	 theoretically	 could	 be	 triggered	 by	 solid	 organ	 transplanta-
tion.22,23 However, even though the concept of tolerance induction 
through	HSCT	was	established	more	than	2	decades	ago,	long-	term	
follow-	up	data	from	patients	after	sequential	transplantation	of	he-
matopoietic stem cells and renal allografts from the same donor are 
mostly	monocentric	and	limited	by	small	patient	numbers	or	a	short	
follow-	up.10,18,24	Moreover,	due	to	the	limited	patient	numbers,	com-
parisons	 to	conventionally	 transplanted	patients	were	not	 feasible	
and so far, uncertainty remains whether tolerance truly improves 
renal allograft survival.
In	 this	 study	we	 aimed	 at	 analyzing	 the	 long-	term	outcome	of	
patients	 after	 sequential	 HSCT	 and	 RT	 from	 the	 same	 donor	 by	
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lected	follow-	up	data	of	published	cases	of	renal	transplantations	after	hematopoi-
etic stem cell transplantation from the same donor and compared patient and 
transplant	kidney	survival	as	well	as	function	with	caliper-	matched	living-	donor	renal	
transplantations	from	the	Austrian	dialysis	and	transplant	registry.	Overall,	22	toler-
ant	and	20	control	patients	were	included	(median	observation	period	10	years	[range	
11	months	to	26	years]).	In	the	tolerant	group,	no	renal	allograft	loss	was	reported,	
whereas 3 were lost in the control group. Median creatinine levels were 85 μmol/l 
(interquartile	range	[IQR]	72-	99)	in	the	tolerant	cohort	and	118	μmol/l	(IQR	99-	143)	in	
the	control	group.	Mixed	linear-	model	showed	around	29%	lower	average	creatinine	
levels	throughout	follow-	up	in	the	tolerant	group	(P < .01). Our data clearly show sta-
ble	renal	graft	function	without	long-	term	immunosuppression	for	many	years,	sug-
gesting	permanent	donor-	specific	 tolerance.	Thus	sequential	 transplantation	might	
be	an	alternative	approach	for	future	studies	targeting	tolerance	induction	in	renal	
allograft recipients.
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comparing renal allograft function and patient survival with a 
matched cohort of conventionally transplanted live donor kidney re-
cipients	from	the	Austrian	Dialysis	and	Transplant	Registry	(OEDTR).
2  | METHODS
2.1 | Systematic literature research
To	analyze	the	long-	term	outcome	of	patients	after	sequential	HSCT	
and RT from the same donor, we conducted a systematic literature 
search	in	PubMed	and	the	Cochrane	database.	In	addition,	the	refer-
ences of all relevant papers were manually reviewed for further re-
ports.	Studies	describing	combined	HSCT	and	RT	were	not	included	
because	of	different	clinical	conditions	(mixed	chimerism	vs	full	chi-
merism,	patients	with	ESRD	but	without	preexisting	malignant	co-
morbidity)	and	different	study	designs.
2.2 | Data retrieval
First, corresponding authors of the papers identified in the litera-
ture	search	were	contacted	and	asked	for	follow-	up	data.	Data	were	
fully anonymized, or anonymization was performed immediately 
after	reception.	Patients	were	included	in	the	analysis	if	the	follow-
	up	 period	was	 longer	 than	 originally	 described	 in	 the	 case	 report	
or additional information concerning patient or renal graft survival 
was	available.	Some	authors	reported	that	further,	unpublished	pa-
tients with previous HSCT from the same donor were transplanted. 
These patients were also included in our analysis. The analysis was 
conducted in accordance with the guidelines of good clinical prac-
tice	and	approved	by	the	ethics	committee	of	the	Medical	University	
of	Vienna	(EK	#	1218/2017	and	1535/2012).
2.3 | Requested parameters
Basic	demographic	and	clinical	characteristics	were	extracted	from	
the reports: gender, relation of donor, age at each transplantation, 
indication	 for	 HSCT,	 cause	 of	 ESRD,	 HLA-	mismatch,	 immunosup-
pressive	regimen	after	RT,	creatinine	at	each	follow-	up	(μmol/l), epi-
sodes of GVHD, incidence of rejection of the renal allograft and date 
of	last	follow-	up.
2.4 | Control group of conventionally transplanted 
living- donor recipients
To	compare	the	 long-	term	patient	and	transplant	kidney-	survival	
of	 sequentially	 with	 conventionally	 transplanted	 patients,	 data	
from	 recipients	 of	 renal	 transplants	 were	 extracted	 from	 the	
OEDTR.25	The	OEDTR	was	established	by	the	Austrian	Society	of	
Nephrology	in	1970	and	has	almost	complete	follow-	up.	The	reg-
istry	comprises	data	extracted	from	the	original	medical	records,	
which	were	created	by	the	responsible	physician	at	the	time	of	a	
patient’s	follow-	up	visit.	All	recorded	ESRD	patients	who	received	
their	 first	 single-	organ	kidney	 transplant	 from	a	 living	donor	be-
tween	1990	and	2012,	were	eligible	for	this	study	and	followed	up	
until	2014	 (N	=	724).	To	achieve	a	more	balanced	analysis	of	 the	
long-	term	renal	allograft	function,	we	excluded	patients	who	lost	
F IGURE  1 Flow chart illustrating data 
retrieval and further patient selection for 
the matching procedure
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their	renal	allograft	within	the	first	3	months	 (Figure	1).	Because	
this general patient population differs from the population of tol-
erant patients due to their medical history, we decided to match 
patients from each group according to immunologic and clinical key 
characteristics	(Table	1).	Caliper-	matching	criteria	were	chosen	re-
flecting	the	previously	described	influence	of	those	parameters	on	
long-	term	transplant	kidney	survival	and	the	availability	of	patient	
information	 common	 in	 the	 literature	 data	 and	 the	OEDTR.26-28 
We	 aimed	 at	 a	 1:1	matching	 because	 of	 the	 limited	 pool	 of	 po-
tential	 matching	 candidates	 from	 the	 OEDTR	 once	 all	 criteria,	
especially	optimal	HLA	match,	 and	missing	data	were	 taken	 into	
account.	Patients	were	selected	from	the	OEDTR	without	replace-
ment, such that each control patient occurred only once. Only if 
for	a	given	sequential	patient	no	other	suitable	matching	partner	
was found in the registry data, we allowed that a single individual 
from	 the	OEDTR	acted	 as	partner	 for	more	 than	one	 sequential	
patient.	 The	 rationale	 for	 this	was	 the	 extraction	 of	 a	 subgroup	
from	the	OEDTR	that	is	as	close	to	the	group	of	literature	patients	
as	possible	while	still	retaining	reasonable	variability	within	the	se-
lected	subgroup.	Differences	between	the	groups	for	several	key	
characteristics	 are	 quantified	 as	 standardized	 mean	 differences	
(SMDs),	which	express	the	difference	of	the	means	between	the	
groups in units of the pooled standard deviation.
The	main	analyses	presented	here	used	a	matching	based	on	the	
variables	 that	were	 available	 for	 each	patient.	By	 varying	 the	 size	
of the control group and allowing more matches for each tolerant 
patient and drawing patients with and without replacement from the 
OEDTR,	we	checked	how	sensitive	the	results	from	statistical	anal-
ysis were to the choice of the control group. Furthermore, results 
were	 compared	 to	 analyses	 done	on	matchings	 based	on	patients	
with complete data only.
2.5 | Statistical analysis
Metric	variables	are	expressed	as	mean	and	standard	deviation	or	
median	 and	 range	 (interquartile	or	 absolute).	Categorical	 variables	
are	expressed	as	absolute	and	relative	frequencies.	Transplant	kid-
ney	 and	 patient	 survival	 are	 depicted	 using	 Kaplan-	Meier	 graphs.	
Due	to	the	low	number	of	events	overall	as	well	as	crossing	Kaplan-	
Meier	 curves,	 we	 used	 the	 Uno	 c-	index	 to	 compare	 the	matched	
tolerant and conventional group.29	 It	 can	be	 interpreted	as	 a	 con-
ditional	 probability	 that	 for	 any	 pair	 of	 tolerant	 and	 conventional	
Variable Tolerant patients
Conventional RT
Matched SMD Pre- matching SMD
Number	of	
patients
22 20 — 707 —
Age	at	RT*	(y) 33 (14) 33 (15) 4% 39 (17) 33%
Age	of	kidney	
donor*	(y)
46 (13) 47 (11) 5% 49 (11) 27%
Sex	match	at	renal	
transplantation*	
(matched)
12	(55%) 12	(60%) 10% 268	(38%) 23%
Sex	(female) 10	(46%) 8	(40%) 10% 241	(34%) 35%
Overall serum 
creatinine after 
RT (μmol/l)
85 (72, 99) 118 (99, 143) — 142 (115, 178) —
Median total 
follow-	up	time	(y)
10 (7, 22) 11 (10, 14) — 7 (4, 13) —
Mean	number	of	
mismatched	HLA	
antigens	at	RT*
0 (0) 0.3 (0.5) 84% 2.9 (1.6) 172%
Mean	number	of	
mismatched	HLA	
antigens at HSCT
1 (1.3) —
Age	at	HSCT	(y) 23 (17, 30) —
Time	between	
HSCT and RT (y)
5 (3, 9) —
Median IS free 
amount of 
follow-	up	(%)
90 (59, 100) Patients are treated with immunosuppression 
throughout	follow-	up
Patient	characteristics	compared	between	the	tolerant	and	conventional	groups.	Standardized	mean	
differences	were	computed	to	quantify	the	difference	between	the	groups	before	and	after	match-
ing.	Variables	noted	by	*	were	used	in	the	matching	procedure.	Data	presented	by	mean	(standard	
deviation),	median	(first	quartile,	third	quartile),	or	absolute	frequency	(relative	frequency).
TABLE  1 Patient characteristics 
compared	between	sequential	and	
conventional group
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patients, the risk of an event (graft loss or death) is higher for the 
control	patient.	Longitudinal	measurements	of	serum	creatinine	lev-
els	were	investigated	using	a	linear	mixed	model	in	which	the	group	
status	is	entered	as	main	variable	of	interest.	We	used	a	random	in-
tercept	and	random	slope	to	accommodate	the	patient-	specific	tra-
jectories	of	 the	 creatinine	 levels.	 Interaction	 terms	with	 follow-	up	
time, nonlinear effects of time using natural splines and different 
random	effect	structures	were	assessed	by	means	of	the	Akaike	in-
formation	criterion	(AIC)	to	improve	model	fit.	Normality	of	residuals	
was	checked	to	ensure	validity	of	the	model.	Other	variables	such	as	
recipient’s	age	at	RT,	HLA-	mismatch	(set	to	0	for	HSCT	patients),	sex	
match	between	donor	and	recipient,	and	donor	age	were	 included	
in the model to assess whether differences in patient characteris-
tics	between	the	tolerant	and	conventional	group	were	adequately	
controlled	for	by	the	matching	procedure.	All	tests	performed	were	
two-	sided	and	a	P < .05 was considered statistically significant. Data 
management	 and	 analysis	 was	 performed	 by	 SAS	 software	 (SAS	
Institute	Inc.,	Cary,	USA)	and	the	R	statistical	software	(R	Core	Team,	
Vienna,	Austria).
2.6 | Data retrieval and patient characteristics in 
sequential group
After	examination	of	all	search	results,	18	relevant	reports	(published	
1991-	2017)	were	found,	describing	29	patients	with	sequential	renal	
and hematopoietic stem cell transplantation (Figure 1).5–21,24	Authors	
of	15	reports	sent	follow-	up	data	for	a	total	of	18	patients.	Despite	
intensive	efforts,	data	from	the	other	reports	were	not	available	be-
cause	patients	were	lost	to	follow-	up	soon	after	the	transplantation	
or	 publication.	 Four	 patients	 (N7,	N8,	N19,	N21),	 not	 described	 in	
TABLE  3 Detailed	clinical	patient	and	follow-	up	findings
No. Follow- up (y)
Creatinine at last 
follow- up (μmol/l) GVHD after RT Death Ref. Note
1 26 133.0 N N (6)
2 24 97.0 N N (12) Diagnosis of radiation induced pulmonary 
fibrosis	in	2000;	lung	transplantation	in	2011
3 23 79.7 N N (13) HCV	cirrhosis	(Child-	Pugh	A),	Diabetes	mellitus	
type 2
4 19 106.1 N N (14)
5 13 NK N Y (14) Died of unknown cause
6 10 106.2 N N (14)
7 5 68.1 N Y NP Died of unknown cause, 11 y after RT
8 9 76,9 NK N NP
9 17 80.0 N Y (7) Died of unknown cause, 20 y after RT
10 12 79.0 N Y (8) Died 12 y after RT with functioning transplant 
kidney, cause of death presumed cardiac
11 10 131.0 N N (9)
12 10 69.9 N N (9)
13 9 81.0 NK N (15)
14 6 97.2 N N (11)
15 6 87.6 N N (16) Second RT, successful pregnancy 4 y after 
second renal transplantation
16 10 80 Y N (17) HCV	cirrhosis	(Child-	Pugh	A),	manifestation	of	
GVHD: cutaneous
17 11 48.0 Y N (18) Manifestation of GVHD: cutaneous and 
musculoskeletal: scleroderma of lower and 
upper	extremity,	skin	flare,	avascular	necrosis	
of knees, hips, shoulders, ankles; diagnosis of 
squamous	cell	carcinoma	of	the	palate	in	
2016, currently in remission
18 4 99.1 N N (19)
19 1 93.8 N N NP
20 22 53.0 Y N (24) Manifestation of GVHD: increase of liver 
function impairment (first seen after HSCT)
21 2 106.0 N N NP
22 1 96.0 Y N (21) Manifestation of GVHD: oral mucosa (mild)
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the	literature	before,	were	included.	Patient	N19	was	transplanted	
and	 followed-	up	at	our	clinic.	The	median	observation	period	was	
10 years (range 11 months to 26 years). Demographic, clinical, and 
transplant-	associated	parameters	are	summarized	and	compared	to	
the	conventional	group	in	Table	1.	A	more	detailed	description	of	all	
tolerant	patients	is	shown	in	Tables	2	and	3.	Except	for	one	patient,	
all indications for HSCT were of hematologic origin. Two patients re-
ceived	their	renal	transplants	from	unrelated	but	fully	HLA-	matched	
donors. Compared to the conventional group, the tolerant patients 
did	not	receive	any	 immunosuppressive	treatment	during	>90%	of	
the	whole	follow-	up	period.
2.7 | Matching of the OEDTR control group
All	22	patients	could	be	included	into	the	matched	comparison.	We	
identified	707	patients	from	the	OEDTR	who	met	our	inclusion	cri-
teria. Twenty patients were selected as matching partners for the 
tolerant	 group	 (Table	1).	 Causes	 of	 ESRD	 in	 these	 patients	 were	
vascular nephropathy (N = 1), glomerulonephritis (N = 5), and 14 pa-
tients	were	labeled	as	“other”	cause	of	ESRD.	Four	patients	had	type	
2	diabetes,	and	2	of	them	developed	diabetes	after	transplantation.	
The	matching	procedure	 reduced	almost	all	SMDs	 into	acceptable	
ranges.	The	SMD	in	the	HLA	mismatches	remained	high	even	after	
matching, which is due to the lack of mismatches in the group of 
sequentially	transplanted	patients.
2.8 | Maintenance immunosuppression
Withdrawal of immunosuppression in the tolerant group: Seven 
patients did not receive any immunosuppression after renal trans-
plantation.	All	other	patients	received	at	least	short-	term	immuno-
suppression	 initially	 after	RT	 (see	Table	2),	which	was	 successfully	
withdrawn	in	the	later	course.	At	the	time	of	the	last	follow-	up,	20	
of	21	patients	(records	not	available	in	one	patient)	were	free	of	im-
munosuppression.	Patient	N2	successful	withdrew	 IS	after	RT	but	
developed	a	radiation-	induced	pulmonary	fibrosis	in	the	later	course	
and	 IS	 including	steroids	and	azathioprine	had	to	be	reinitiated.	 In	
2011, a successful lung transplantation was performed and tacroli-
mus was added. Maintenance IS in the control group was given as 
per	the	local	center	standards,	that	is,	calcineurin	inhibitor	(CNI),	my-
cophenolate mofetil (MMF), and steroids in all patients aiming at tac-
rolimus	(TAC)	troughs	between	4	and	8	ng/ml	after	the	first	years.
3  | RESULTS
3.1 | Overall renal allograft survival and graft 
function in sequentially transplanted patients 
compared to conventional transplanted patients
No	graft	 loss	was	reported	 in	the	tolerant	group,	whereas	3	 (15%)	
were	 lost	 in	 the	 control	 group	 (Kaplan-	Meier	 analysis	 depicted	 in	
Figure	2).	The	corresponding	Uno	c-	index	comparing	 the	2	groups	
was 0.81, suggesting an improved renal graft survival in the tolerant 
group	within	the	study	period.	The	95%	confidence	 interval	 (0.67-	
0.96)	excluded	parity	 (0.5),	providing	evidence	against	the	hypoth-
esis	 that	 the	renal	allograft	survival	probabilities	are	equal	 in	both	
groups (P < .001).
Serum creatinine levels over the whole study period are depicted 
in Figure 3, median serum creatinine levels were 85 μmol/l (first 
quartile	72,	 third	quartile	99)	and	118	μmol/l	 (IQR	99-	143)	 for	 the	
tolerant and conventional group, respectively. In a crude compari-
son ignoring the longitudinal nature of the data, the median level in 
the conventional group was significantly higher than in the tolerant 
group	(Mann-	Whitney	U test P < .001).
Figure	4	 shows	 results	 from	 the	mixed-	model	 analysis	of	 log2-	
transformed serum creatinine levels, taking the study design into 
F IGURE  2 Kaplan-	Meier	plot	of	transplant	kidney	survival;	shaded	areas	and	dashed	lines	represent	95%	confidence	intervals.	No	transplanted	
kidney	was	lost	in	the	group	of	sequentially	transplanted	patients.	RT,	renal	transplantation	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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account. No relevant difference in the change of creatinine levels 
over	 time	 between	 the	 2	 groups	was	 found	 (interaction	with	 fol-
low-	up	time	was	not	included	in	the	models,	either	by	checking	sig-
nificance	or	by	AIC).	The	effect	of	time	was	found	to	be	nonlinear	(a	
model including spline terms of time using 3 knots showed improved 
AIC),	with	a	decrease	in	creatinine	levels	shortly	after	transplanta-
tion. Group status was significant in the model (P = .006), providing 
evidence that serum creatinine levels in the tolerant group are on 
average	 29%	 lower	 than	 in	 the	 conventional	 group.	 Estimated	 ef-
fects	of	group	status	remained	stable	regardless	of	modeling	of	time.	
After	inclusion	of	other	relevant	key	characteristics,	group	status	re-
mained significant (P	=	.045),	whereas	none	of	the	other	variables	in	
the model had significant results. In an unmatched analysis, compar-
ing	all	patients	from	the	OEDTR	with	available	creatinine	measure-
ments	(N	=	273)	and	the	study	group,	the	OEDTR	patients	exhibited	
a trend toward higher creatinine values over time (Figure S1).
In	 a	 subset	 of	 patients	 further	 immunologic	 assays	 have	 been	
performed.	 Both	 patients	 had	 no	 signs	 of	 humoral	 immune	 ac-
tivation	 (measured	 as	 donor-	 and	 recipient-	specific	 antibodies).	
Moreover,	protocol	biopsies	performed	one	and	12	months	after	RT	
revealed	 no	 signs	 of	 allograft	 rejection.	Notably,	 recipient-	derived	
T	cells	measured	before	RT	and	1	year	after	remained	virtually	un-
changed (Figure 5).
3.2 | Overall patient survival in sequentially 
transplanted patients compared to conventionally 
transplanted patients
Of 22 patients, 4 deaths were reported. Patient N5 was lost to 
follow-	up	13	years	after	RT	and	died	in	the	later	course.	The	exact	
time of death is not recorded and the patient is therefore treated as 
censored	at	the	last	follow-	up	visit.	Patient	N7	was	last	seen	5	years	
after transplantation at the treating medical center and died 11 years 
after renal transplantation. Patient N9 was last seen in 2012, 17 
years	 after	 renal	 transplantation.	 At	 that	 time,	 her	 creatinine	was	
in	normal	range.	Later,	no	more	visits	to	the	outpatient	clinic	were	
recorded.	She	died	in	2015.	All	3	patients	died	of	unknown	causes.	
Patient N10 died in 2014, 12 years after RT. His presumed cause of 
death	was	of	cardiac	origin.	Notably,	 the	patient	died	with	a	 func-
tioning transplant kidney.
Two	deaths	were	recorded	in	the	matched	subset	of	convention-
ally	transplanted	patients	from	the	OEDTR.	The	Uno	c-	index	for	the	
corresponding	Kaplan-	Meier	survival	curves	comparing	the	2	groups	
was 0.39, suggesting a lower mortality in the conventional group 
within	the	study	period	(Figure	6).	However,	due	to	the	low	number	
of	events,	the	95%	confidence	interval	was	wide	(0.08-	0.71)	and	in-
cluded parity (0.5), thus lacking evidence against the hypothesis that 
the	overall	survival	probabilities	are	equal	in	both	groups	(P = .54).
3.3 | Further notable events in the patients′ 
later course
After	 HSCT,	 patient	 N15	 received	 a	 renal	 allograft	 from	 a	 fully	
matched	 deceased	 donor.	 Eight	 years	 later,	 the	 allograft	 was	
lost due to infection and a second renal transplantation was per-
formed, in which the previous HSCT donor (mother) donated a 
kidney. Withdrawal of all immunosuppressive drugs was success-
ful	10	weeks	later.	Four	years	later,	the	patient	gave	birth	to	a	child	
without	rejection.	The	patient	developed	HLA	antibodies	but	they	
were not targeted against the allograft. Restart of immunosuppres-
sive therapy was not needed in the further course.
Follow-	up	data	(exceeding	the	published	report)	regarding	graft	
function	or	patient	survival	from	one	patient	described	by	Beitinjaneh	
et	al	were	not	available.20 Nevertheless, the treating center reported 
3	 further	 patients	 not	 described	 before,	 who	 received	 sequential	
HSCT	and	RT.	The	HSCTs	were	performed	between	1982	and	1986	
(indications:	acute	myeloid	leukemia	[AML],	aplastic	anemia,	chronic	
myeloid	 leukemia	 [CML]).	 Renal	 allografts	 were	 transplanted	 6	 to	
F IGURE  3 Comparison of serum 
creatinine	levels	(on	log2	scaled	axis)	after	
RT	between	groups;	the	mean	is	indicated	
as	diamond	shape	in	the	boxplots	[Color	
figure	can	be	viewed	at	wileyonlinelibrary.
com]
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20	years	later	(median	16	years).	All	three	patients	died	(33,	14,	and	
26 years after HSCT). Due to a lack of further patient data (donor 
age,	course	of	creatinine,	HLA	mismatch,	 immunosuppressive	regi-
mens), we did not include these patients in our analysis.
4  | DISCUSSION
The	induction	of	donor-	specific	tolerance	remains	the	holy	grail	 in	
transplantation. Currently, the only clinically successful concept to 
establish	donor-	specific	tolerance	to	a	renal	graft	is	via	HSCT	from	
the	same	donor.	However,	widespread	use	 is	hampered	mainly	by	
cytotoxic	 preconditioning	 before	 bone	 marrow	 transplantation.	
Thus,	 few	patients	have	been	 reported	 in	 the	 literature	 that	have	
received	 combined	HSCT	 and	RT	 from	 the	 same	donor	 solely	 for	
the purpose of tolerance induction. However, several patients have 
been	reported	who	had	received	an	HSCT	for	a	conventional	indi-
cation	(eg,	a	hematologic	malignancy)	and	subsequently	received	a	
kidney	from	the	same	donor.	The	aim	of	our	study	was	to	contribute	
long-	term	data	of	such	tolerant	patients	and	to	compare	those	find-
ings with matched living donor transplant recipients under conven-
tional IS.
Compared to previous studies, our analysis represents the larg-
est	and	longest	follow-	up	observation	of	this	specific	patient	popu-
lation	and	includes	additional	patients	not	described	in	the	literature	
before.	One	of	our	major	findings	is	that	over	a	total	observation	pe-
riod	of	250	patient-	years	not	one	single	allograft	loss	was	recorded.	
Moreover,	kidney	function	was	significantly	better	compared	to	our	
matched group of conventionally living donor recipients. There are 
several	reasons	that	might	attribute	to	these	results.	First,	 in	addi-
tion to receiving initial IS immediately after RT, most of the tolerant 
patients were successfully withdrawn from immunosuppression, 
thus	 adverse	 side	 effects	 and	 nephrotoxicity	 caused	 by	 conven-
tional IS regimens were largely avoided.30 Moreover, in tolerant 
patients without the need of ongoing immunosuppressive therapy, 
adherence, which is a main risk factor for chronic allograft loss, is 
of	no	concern	and	the	 likelihood	of	 infections	might	be	 lower.31,32 
Furthermore	 it	 must	 be	 addressed,	 that	 this	 highly	 selected	 sub-
group	of	the	OEDTR	represents	patients	with	comparably	promising	
clinical	parameters	(young	age,	low	HLA	mismatch)	and	hence	may	
not	be	representative	of	the	general	population	of	kidney	transplant	
recipients.	On	 the	 other	 hand,	 it	must	 also	 be	 pointed	 out	 that	 4	
patients	from	the	study	group	died	in	the	further	follow-	up	period.	
Nevertheless, death censoring was applied within our analysis, con-
sidering that our primary aim was to evaluate the impact of toler-
ance on renal graft survival and taking the previous mostly severe 
hemato-	oncologic	 diseases	 in	 this	 special	 group	 of	 patients	 into	
account.
Despite significantly higher serum creatinine levels in the con-
trol	group	and	3	renal	graft	losses	in	the	follow-	up,	no	relevant	dif-
ference in the change of creatinine levels over time was found. The 
reason	for	this	may	also	be	the	selection	of	the	control	group,	rep-
resenting patients with a very good outlook after transplantation. In 
an	unmatched	analysis,	comparing	all	OEDTR	patients	with	the	se-
quential	patients,	the	OEDTR	patients	exhibit	a	trend	toward	higher	
creatinine values over time. When interpreting the creatinine slopes 
F IGURE  4 Mixed	model	for	log2-	transformed	serum	creatinine	levels	modeling	time	using	natural	splines	with	3	knots.	Estimates	were	
transformed	to	original	scale.	The	shaded	areas	around	the	model	estimates	constitute	95%	confidence	intervals.	The	overall	difference	
between	the	2	groups	was	significant.	No	relevant	difference	in	the	change	of	creatinine	levels	over	time	between	the	2	groups	was	
found.	Four	patients	from	the	control	group	had	to	be	excluded	due	to	missing	longitudinal	serum	creatinine	measurements.	We	restricted	
the	analysis	to	the	first	14	years	after	RT	due	to	lack	of	serum	creatinine	measurements	for	most	OEDTR	patients	thereafter.	RT,	renal	
transplantation	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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of the control patients, one may further conclude that, in line with 
recent	findings	from	Gaston	et	al,	those	graft	losses	could	be	associ-
ated	with	new-	onset	allograft	dysfunction	in	the	later	course,	rather	
than a slow process of continuous worsening of allograft function.33 
Unfortunately, clinical data from the control group were limited and 
more detailed information regarding the cause of the renal graft 
losses	were	not	available.
So far, 3 centers in the United States reported results from 
their prospective trials of simultaneous HSCT and RT where IS was 
successfully	withdrawn	in	a	considerable	number	of	patients.34-37 
Nevertheless,	complications	such	as	in	part	severe	bacterial,	viral,	
or	 fungal	 infections	were	 described.35,36 Due to these risks, the 
use	of	combined	transplantations	solely	for	the	purpose	of	toler-
ance	induction,	 is	subject	to	considerable	controversy,	especially	
in patients who may do well on conventional immunosuppression. 
Our	data	on	the	other	hand	indicate	a	sustained	long	term	benefit	
regarding transplant kidney function in patients after tolerance in-
duction via hematopoietic stem cell transplantation from the same 
donor.
About	two-	thirds	of	the	patients	in	our	analysis	received	at	least	
short-	term	immunosuppressive	therapy	after	RT,	which	was,	except	
for one patient (N2, lung transplantation), successfully withdrawn in 
the	later	course.	Notably,	none	of	the	tolerant	patients	was	taking	
long-	term	corticosteroid	treatment.
Most patients received IS for the prevention of a potential 
GVHD episode. Manifestations of a GVHD were reported in 4 pa-
tients (N16, N17, N20, N22). They included skin and musculoskeletal 
lesions, increased liver enzymes, or mild restrictive lung disease. 
Thus, considering the risk of even at least temporary IS, we think 
there is enough evidence to support minimalization of IS after kid-
ney	transplantation	in	GVHD-	free	and	tolerant	patients.	Notably,	a	
steroid	 taper	 around	RT	 seems	 to	 be	 beneficial,	mainly	 to	 reduce	
ischemia-	reperfusion	injury	which	is	a	well-	known	cause	for	initial-	
transplant kidney dysfunction.38,39
There	are	some	limitations	in	our	study	that	need	to	be	addressed	
when	 interpreting	 the	 results.	 First,	 a	 publication	 bias	 cannot	 be	
ruled	out.	It	might	be	that	unsuccessful	cases	were	not	reported	in	
the literature and therefore not included in this study. However, this 
seems	to	be	unlikely,	given	the	novelty	of	this	hypothetical	issue,	the	
rarity	of	an	available	donor	for	both	HSCT	and	RT	when	needed,	and	
the	limited	number	of	centers	with	the	infrastructure	and	experience	
to	perform	sequential	transplantations.
Despite	frequent	communications	with	the	authors	or	their	suc-
cessors,	we	were	not	able	to	gather	outcome	data	of	all	29	published	
patients.	We	tried	to	minimize	this	limitation	by	including	further	pa-
tients	that	have	been	sequentially	 transplanted	but	have	not	been	
published	 in	 the	 literature.	 Furthermore,	 due	 to	 the	 retrospective	
design	of	our	study	and	the	long	period	between	the	publication	of	
the	 first	cases	and	our	analysis,	 the	quantity	of	collectable	data	 is	
limited	and	varied	strongly	between	different	patients.	We	therefore	
focused	our	 analysis	 on	basic	 parameters	 such	 as	 renal	 transplant	
function and patient survival. Unfortunately, this also implies that 
tests	for	donor	specific	antibodies	(DSAs)	or	chimerism	persistence	
are	missing.	Hence,	we	added	supplemental	material	describing	the	
F IGURE  6 Kaplan-	Meier	plot	of	
overall patient survival; shaded areas and 
dashed	lines	represent	95%	confidence	
intervals. Overall there were 4 deaths in 
the	sequential	group	but	one	was	treated	
as	censored	at	the	last	follow-	up	visit	as	
the	exact	time	of	death	is	unknown.	RT,	
renal	transplantation	[Color	figure	can	be	
viewed	at	wileyonlinelibrary.com]
F IGURE  5  (A)	Clinical	course	of	the	2	tolerant	patients	transplanted	at	our	center	(pat.	N18	and	N19).	Both	patients	underwent	
transplantation	with	only	a	short	steroid	taper	to	reduce	ischemia-	reperfusion	injury.	No	further	immunosuppression	was	administered.	
(B)	Humoral	immune	activation	was	assessed	by	measuring	donor-	and	recipient-	specific	antibodies.	There	were	no	signs	of	humoral	immune	
activation.	(C)	Chimerism	was	assessed	via	real-	time	PCR	in	separated	T	cells	before	and	1	year	after	RT	in	both	patients.	The	proportion	of	
recipient-	derived	T	cells	was	low	and	virtually	didn’t	change	over	the	time.	(D)	Protocol	biopsies	performed	1	month	and	12	months	after	
RT	showed	structurally	regular	renal	tissue	with	no	signs	of	cell-	or	antibody-	mediated	rejection.	Data	from	patient	N18	have	been	shown	
previously	(Schwarz	2016)	with	a	shorter	follow-up19	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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lack	of	DSAs,	good	transplant	kidney	function,	as	well	as	a	virtually	
unchanged	proportion	of	recipient-	derived	T	cells	in	the	2	sequen-
tially transplanted patients from our center.
Furthermore,	 even	 if	 publication	bias	 is	 ignored,	 the	 statistical	
power	of	this	study	to	accurately	estimate	differences	between	tol-
erant patients and conventionally transplanted patients is limited 
due	to	the	relatively	low	number	of	available	patients.
In	 conclusion,	 our	 data	 with	 greater	 numbers	 and	 lengthier	
	follow-	up	 than	 previously	 available	 indicate	 that	 tolerant	 patients	
after	 HSCT	 maintain	 a	 better	 function	 of	 their	 transplant	 kidney	
than	comparable	patients	under	conventional	 immunosuppression.	
Furthermore, overall renal graft and patient survival was at least 
comparable,	and	allowing	for	limitations	of	the	analysis,	perhaps	su-
perior to a matched living donor cohort. These data lend support 
to	efforts	currently	underway	to	utilize	co-	transplantation	of	donor	
hematopoietic	stem	cells	to	improve	outcome	in	larger	numbers	of	
renal transplant patients.
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